Literature DB >> 22729281

Acute mucosal radiation reactions in patients with head and neck cancer. Patterns of mucosal healing on the basis of daily examinations.

A Wygoda1, K Składowski, T Rutkowski, M Hutnik, M Goleń, B Pilecki, W Przeorek, B Lukaszczyk-Wideł.   

Abstract

PURPOSE: The goal of this research was to evaluate the healing processes of acute mucosal radiation reactions (AMRR) in patients with head and neck cancer.
MATERIALS AND METHODS: In 46 patients with oral and oropharyngeal cancer patients irradiated with conventional (n = 25) and accelerated (n = 21) dose fractionation AMRR was evaluated daily during and after radiotherapy. Complex of morphological and functional symptoms according to the Dische score were collected daily until complete healing.
RESULTS: Duration of healing after the end of radiotherapy ranged widely (12-70 days). It was on the average 8 days longer for accelerated than for conventional radiotherapy (p = 0.016). Duration of dysphagia was also longer for accelerated irradiation (11 days, p = 0.027). Three types of morphological symptoms were observed as the last symptom at the end of AMRR healing: spotted and confluent mucositis, erythema, and edema. Only a slight correlation between healing duration and area of irradiation fields (r = 0.23) was noted. In patients with confluent mucositis, two morphological forms of mucosal healing were observed, i.e., marginal and spotted. The spotted form was noted in 71% of patients undergoing conventional radiotherapy and in 38% of patients undergoing accelerated radiotherapy. The symptoms of mucosal healing were observed in 40% patients during radiotherapy.
CONCLUSION: The wide range of AMRR healing reflects individual potential of mucosa recovery with longer duration for accelerated radiotherapy. Two morphological forms of confluent mucositis healing were present: marginal and spotted. Healing of AMRR during radiotherapy can be observed in a significant proportion of patients.

Entities:  

Mesh:

Year:  2012        PMID: 22729281     DOI: 10.1007/s00066-012-0146-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  24 in total

1.  A pilot study of postoperative CHART and CHARTWEL in head and neck cancer.

Authors:  N Shah; M I Saunders; S Dische
Journal:  Clin Oncol (R Coll Radiol)       Date:  2000       Impact factor: 4.126

2.  Accelerated radiation therapy, seven fractions per week, for advanced head and neck cancer--a feasibility study.

Authors:  Joe M O'Sullivan; Donal P Hollywood; Nuala Cody; Joe Dillon; Steve Buckney; Michael J Moriarty; John G Armstrong
Journal:  Clin Oncol (R Coll Radiol)       Date:  2002-06       Impact factor: 4.126

3.  Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel : a phase II study.

Authors:  Robert Semrau; Susanne Temming; Simon Florian Preuss; Jens Peter Klubmann; Orlando Guntinas-Lichius; Rolf-Peter Müller
Journal:  Strahlenther Onkol       Date:  2011-09-23       Impact factor: 3.621

4.  Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial.

Authors:  Krzysztof Skladowski; Boguslaw Maciejewski; Maria Golen; Rafal Tarnawski; Krzysztof Slosarek; Rafal Suwinski; Mariusz Sygula; Andrzej Wygoda
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-01       Impact factor: 7.038

5.  High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer.

Authors:  Hendrik Andreas Wolff; Jan Bosch; Klaus Jung; Tobias Overbeck; Steffen Hennies; Christoph Matthias; Clemens F Hess; Ralph M Roedel; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

6.  A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer.

Authors:  S Dische; M Saunders; A Barrett; A Harvey; D Gibson; M Parmar
Journal:  Radiother Oncol       Date:  1997-08       Impact factor: 6.280

7.  Accelerated radiotherapy with delayed concomitant boost in locally advanced squamous cell carcinoma of the head and neck.

Authors:  R MacKenzie; J Balogh; R Choo; E Franssen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-10-01       Impact factor: 7.038

Review 8.  Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review.

Authors:  Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg
Journal:  Radiother Oncol       Date:  2003-03       Impact factor: 6.280

9.  Accelerated postoperative radiotherapy with weekly concomitant boost in patients with locally advanced head and neck cancer.

Authors:  Abderrahim Zouhair; David Azria; Philippe Pasche; Roger Stupp; Julia Chevalier; Michael Betz; René O Mirimanoff; Mahmut Ozsahin
Journal:  Radiother Oncol       Date:  2004-02       Impact factor: 6.280

10.  Oral mucositis in morning vs. evening irradiated patients: a randomised prospective study.

Authors:  Manish Goyal; Pragya Shukla; Deepak Gupta; Shyam Singh Bisht; Ankur Dhawan; Seema Gupta; Mohan Chand Pant; Nar Singh Verma
Journal:  Int J Radiat Biol       Date:  2009-06       Impact factor: 2.694

View more
  3 in total

1.  Smoking during radiotherapy for head and neck cancer and acute mucosal reaction.

Authors:  Beata Szeszko; Karolina Osowiecka; Monika Rucińska; Ewa Wasilewska-Teśluk; Krzysztof Gliński; Lucyna Kępka
Journal:  Rep Pract Oncol Radiother       Date:  2015-05-23

2.  Acute mucosal reactions in patients with head and neck cancer. Three patterns of mucositis observed during radiotherapy.

Authors:  A Wygoda; T Rutkowski; M Hutnik; K Składowski; M Goleń; B Pilecki
Journal:  Strahlenther Onkol       Date:  2013-05-23       Impact factor: 3.621

3.  Prognostic role of tumor volume for radiotherapy outcome in patient with T2 laryngeal cancer.

Authors:  T Rutkowski; A Wygoda; K Składowski; B Hejduk; R Rutkowski; Z Kołosza; B Maciejewski
Journal:  Strahlenther Onkol       Date:  2013-08-29       Impact factor: 3.621

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.